Inhale the future, exhale the past. Welcome, NuvoAir
We like platform plays, big problems, and intrepid founders. Thus, I am excited about our Series A investment into NuvoAir, next to AlbionVC, Amino, and existing investors. Do you recall those moments when all pieces feel like they’re falling together? Since the first call with Lorenzo Consoli (founder), I had that feeling.
Cutting-edge problem. Lifetime cutting, actually.
- Chronic conditions management has been a big domain that suffers from painful information inefficiencies, keeping patients often in the dark, reactive to exacerbations, and subjective in interpretation.
- No difference in chronic respiratory diseases (CRD). The gaps in the current care standards are substantial — unnecessary exacerbations eat quality lifetime of patients triggered frequently by low adherence due to keeping patients in the dark, late in action/reactive, more subjective than desired as poor on patient’s evidence.
- Besides all that, the tools available to patients have been far from an enjoyable experience. If you suffer from an ugly disease, the last thing you need is to use an ugly tool to add up to all the ugliness.
Giant category, giant impact: CRDs produce a massive burden to society.
- One of CRDs, COPD (chronic obstructive pulmonary disease), is the third deadliest disease on this planet.
- ~600 million people suffer from one or another form of CRD globally.
- Costs of care are skyrocket high (~$300bn just in the US) and growing.
A strong candidate for the category winner, sound approach, and love from customers:
- Lorenzo is breathing the problem and living the “reinvented care, longer life” vision. He is a learning and execution machine with the right hunger for great societal outcome and business success and profound founder-market fit.
- NuvoAir is a platform play with data-first approach. The data and their interpretation add a game-changing value to medical devices of the future, broaden care options, and develop better medical outcomes for patients. NuvoAir greatly marries the “customer taste” (slick device and app design, community interaction platform) and the “top grade clinical results” (data platform, interpretation machine intelligence) in an unparalleled way.
- Customer reactions are overwhelmingly positive, as is the intriguing traction in significant early markets like the UK. These are also great signs that preferences of most patients have been changing. Bringing up the desire to understand their own condition, be alerted and in control of care demands and with response at fingertips.
And good tailwinds as a bonus: the remote-first approach, which has accelerated with the pandemia, adds extra propulsion.
There has been a well-fitting asthma quote, some having a similar issue may recall: “If you can’t breathe, nothing else matters”. Wishing all the success to the NuvoAir team on their mission.
